Transcutaneous auricular vagus nerve stimulation for the treatment of irritable bowel syndrome: a pilot, open-label study

Aim: Irritable bowel syndrome (IBS) is a frequent disease, associating chronic abdominal pain and abnormal bowel habits. The sympatho-vagal balance may be altered in IBS. We tested the effect of transcutaneous auricular stimulation of the left vagus nerve (taVNS) on symptoms and physiological and biological variables. Patients & methods: Twelve IBS women agreed to apply taVNS for 6 months. Evaluation was based on feasibility, symptoms, psychological questionnaires, fecal caprotectin, blood cytokines and bowel transit times. Results: Nine patients completed the trial: there was a significant improvement of symptoms at 3 and 6 months although none of the measured variables were modified by taVNS. Conclusion: The results suggest taVNS is feasible and may improve IBS symptoms. Randomized controlled studies are needed to confirm these preliminary results. ClinicalTrials.gov : NCT02420158.

Download Full-text

An open label study to determine the efficacy and tolerability of tegaserod in the treatment of constipation dominant irritable bowel syndrome (IBS-C)

Gastroenterology ◽

10.1016/s0016-5085(03)82696-3 ◽

2003 ◽

Vol 124 (4) ◽

pp. A533 ◽

Cited By ~ 2

Author(s):

Hasnain A. Shah ◽

Wasim Jafri ◽

Javed A. Butt ◽

Aftab Mohsin ◽

Ikramullah Khan

Keyword(s):

Irritable Bowel Syndrome ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Irritable Bowel

Download Full-text

Su1192 - Safety, Tolerability, and Effectiveness of Plecanatide in Patients with Constipation-Predominant Irritable Bowel Syndrome: Long-Term Evidence from an Open-Label Study

Gastroenterology ◽

10.1016/s0016-5085(18)31892-4 ◽

2018 ◽

Vol 154 (6) ◽

pp. S-499

Author(s):

Charles F. Barish ◽

Robert Crozier

Keyword(s):

Irritable Bowel Syndrome ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Irritable Bowel

Download Full-text

Tu1791 An Open-Label Study Evaluating Symptoms and Potential Mechanisms of Serum-Derived Bovine Immunoglobulin/Protein Isolate (SBI) in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

Gastroenterology ◽

10.1016/s0016-5085(16)33202-4 ◽

2016 ◽

Vol 150 (4) ◽

pp. S948

Author(s):

Nelson Valentin Feliciano ◽

Michael Camilleri ◽

Andres Acosta ◽

Paula Carlson ◽

Deborah J. Eckert ◽

...

Keyword(s):

Irritable Bowel Syndrome ◽

Protein Isolate ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Bovine Immunoglobulin ◽

Irritable Bowel

Download Full-text

Igg Food Antibody Guided Elimination-Rotation Diet Was More Effective than FODMAP Diet and Control Diet in the Treatment of Women with Mixed IBS—Results from an Open Label Study

Journal of Clinical Medicine ◽

10.3390/jcm10194317 ◽

2021 ◽

Vol 10 (19) ◽

pp. 4317

Author(s):

Lucyna Ostrowska ◽

Diana Wasiluk ◽

Camille F. J. Lieners ◽

Mirosława Gałęcka ◽

Anna Bartnicka ◽

...

Keyword(s):

Irritable Bowel Syndrome ◽

Abdominal Pain ◽

Control Diet ◽

Dietary Treatment ◽

Control Group ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Irritable Bowel ◽

Fodmap Diet

Irritable bowel syndrome (IBS) is a chronic disease with recurrent abdominal pain, disturbed bowel emptying, and changes in stool consistency. We compared the effectiveness of three different dietary treatment plans (G1-FM-low FODMAP diet, G2-IP IgG based elimination-rotation-diet, and as control group, the G3-K control diet recommended by an attending gastroenterologist) in treating patients diagnosed with mixed irritable bowel syndrome. A total of seventy-three female patients diagnosed with a mixed form of irritable bowel syndrome (IBS-M) were enrolled in the study. The diet of each patient in Group 1 (G1-FM) and 2 (G2-IP) was determined individually during a meeting with a dietitian. Patients from Group 3 (G3-K) received nutrition advice from a gastroenterologist. Significant differences in the reduction of IBS symptoms were found between the groups. IBS symptoms as well as comorbid symptoms significantly improved or disappeared completely in the G2-IP group (idiopathic abdominal pain, p < 0.001; abdominal pain after a meal, p < 0.001; abdominal pain during defecation, p = 0.008), while in the G1-FM group, some of the IBS symptoms significantly improved (mucus in stool, p = 0.031; bloating, p < 0.001). In group G3-K no significant improvement was seen. Based on the results of this open-label study, it was concluded that various dietary interventions in the treatment of IBS-M patients do not uniformly affect the course and outcomes of disease management. Rotation diets based on IgG show significantly better results compared to other diets.

Download Full-text